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Abstract
Cancer development is a complex process with multiple steps. Many factors, including 
radiation, chemicals, viruses, genetic and epigenetic changes, lead to abnormal prolifer-
ation of a single cell, which results in the outgrowth of a population of clonal-derived 
tumour cells. It has established that DNA hypermethylation, an epigenetic mechanism that 
occurred by the addition of a methyl group at 5′ position of the pyrimidine ring of cytosine 
residues at CpG islands through the action of DNA methyltransferase enzymes, has been 
considered as the cause of human tumorigenesis, including breast cancer development. 
Moreover, DNA hypermethylation holds a promising application as a potential biomarker 
for the early detection, prognosis and prediction of drug sensitivity in cancer. Therefore, 
this chapter focuses on the description and exemplification of the DNA hypermethylation 
changes, particularly, highlight the DNA hypermethylation as a potential biomarker 
applied in predictive, diagnostic, prognostic and therapeutic monitoring of breast cancer.
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1. Introduction
Epigenetics, which was first coined by Waddington in 1942, literally means as ‘outside conven-
tional genetics’, refers to the heritable, reversible changes in gene expression that occur without 
alteration DNA sequence [1]. Epigenetic modifications are natural processes and essential for 
mammalian development and cell proliferation. These epigenetic changes could also be affected 
by many random factors or environmental influences. Disruption of epigenetic modification 
resulting in regulating patterns of gene expression is the feature of a number of severe human 
diseases, including malignant cellular transformation [2–4]. Three main epigenetic modifica-
tion systems, including DNA methylation, histone covalent modification, and non-coding RNA 
modification, leading to associated-gene silencing, have been observed [5, 6]. This chapter aims 
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to introduce the reader to the concept of DNA methylation, especially DNA hypermethylation, 
with examples of its involvement in human breast cancer.
2. DNA hypermethylation: a kind of epigenetic modification that plays a 
key role in silencing tumour suppressor genes
DNA methylation is one of the epigenetic mechanisms that is closely associated with normal 
cell development and a number of key processes including imprinting, X-chromosome inactiva-
tion, repression of repetitive element transcription, chromatin organization, etc. [7–9]. Aberrant 
methylation patterns are known to be presented in the genomes of cancer cells. Two patterns 
of aberrant methylation have been observed, including global hypomethylation along the 
genome and hypermethylation at the specific sites, namely the CpG islands (CGIs) within the 
promoter regions, according to the decreased and increased the level of methyl group modifica-
tion, respectively [4, 8, 10–12]. Disordered DNA methylation contributes to a number of human 
diseases, including breast cancer. Increased level of genome-wide hypomethylation results in 
increased chromosomal instability and activation of regulatory DNA sequences, including tran-
scription of oncogenes, retrotransposons as well as genes encoding proteins involved in malig-
nant cell development. DNA methylation refers to a covalent modification of cytosine ring at 
the 5′ position of a CpG dinucleotide by adding a methyl group in the 5th carbon of the ring 
using S-adenosyl methionine as a methyl donor (Figure 1) [8, 12].
This methylation process is catalysed by DNA (cytosine-5) methyltransferases (DNMTs). 
In mammalian, DNMTs are a highly conversed family protein encompassing DNMT1, 
DNMT2, DNMT3A, DNMT3B and DNMT3L, which could be distinguished by their function 
[13–15] (Figure 2). DNMT1 was the first methyltransferase to be discovered [1], then DNMT3 
was discovered and characterized. Regarding to DNMTs function, DNMT3A and DNMT3B 
perform de novo methylation by adding the methyl groups to unmethylated CpG, which is 
responsible for the establishment of new methylation pattern in genomic DNA, whereas 
DNMT1, which has a high preference for hemi-methylated DNA, maintains the existence of 
methylation patterns following DNA replication on the newly synthesized strand [3, 4, 13, 
14, 16, 17]. DNMT3L (DNA (cytosine-5-)-methyltransferase 3-Like) has no catalytic activity, 
DNMT3L has been shown to act as a general stimulatory factor for de novo methylation and 
facilitate methylation of DNMT3A and DNMT3B [2, 18].
The term CpG refers to the base cytosine (C) linked by a phosphate bond to the base Guanine 
(G) in the DNA nucleotide sequence, which usually cluster together in ’CpG islands (CGIs)’ and 
typically locate at or near the promoters and transcription sites of genes. The molecular mecha-
nisms underlying CpG island hypermethylation in many human cancers, including breast can-
cer, have been explored. The hypermethylation of CGIs located at tumour suppressor genes can 
result in transcriptional silencing of genes through a number of mechanisms, including (i) DNA 
hypermethylation directly affects the RNA polymerase II and DNA interactions by inhibiting 
the binding of transcriptional factors on specific sequences, such as AP-2, c-Myc/Myn, E2F, 
NF-κB, etc. and (ii) hypermethylated DNA recruits methyl-CpG binding proteins (MeCP1 and 
MeCP2), and methyl-CpG binding domain protein (MBD1, MBD2, MBD3 and MBD4) [4].
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Figure 1. (A) The DNMTs catalyse the methyl cytosine modification. (B) The structure of SAM and SAH.
Figure 2. The roles of DNMTs.
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Tumour suppressor genes (TSGs) normally suppress or negatively regulate cell proliferation 
by encoding proteins that block the action of growth-promoting proteins. A hallmark of cancer 
involves the loss of function of TSGs through the silencing genetic information. The silencing 
of TSGs by the high levels of 5-methylcytosine in their CpG island promoter regions, consid-
ered as the ’first and second hit‘, is equivalent to mutations and translocations, in Knudson’s 
two-hit model of tumorigenesis [19, 20]. Here, the methyl groups become chemically bonded 
to the cytosine in CGIs, leading to disruption of the normally controlled cell proliferation and 
drive it to malignancy (Figure 3). Thus, the presence of m5CpG dinucleotide in tumour sup-
pressor gene promoters is recognized as an important event in many human tumour types.
3. DNA methylation in circulation as a cancer biomarker
The high presence of cell-free circulating tumour DNA (ctDNA), which is derived from pri-
mary tumour cells, can be found in blood and non-invasive samples of patients with cancer, 
such as urine, brochoalveolar lavage, mammary aspiration fluids, saliva, sputum, etc. makes 
an ideal candidate biomarker for prognosis and early diagnosis of breast cancer. ctDNA can 
be distinguished from circulating DNA derived from healthy cells by the presence of genomic 
aberrant modifications. For example, upon the tumour development, ctDNA carries tumour 
specific epigenetic modifications, i.e. DNA hypermethylation, is released due to the lysis of 
circulating cancer cells or micro-metastases. Therefore, the detection of genetic and epigen-
etic alterations in ctDNA offers a potential source of development of prognostic and pre-
dictive biomarkers for cancer. Quantitative evaluation of ctDNA can reflect tumour burden 
relevant to provide information on genetic and epigenetic profiles associated with human 
cancer development. The concentration of methylated ctDNA is presented in an even smaller 
portion of this amount, thus, presenting a challenging substrate to work with. Fortunately, 
even in the low concentration, ongoing technical developments and much of the progress in 
Figure 3. The typical CpG island of a tumour suppressor gene is represented in a normal and a tumour cell. White dots: 
unmethylated CpG; black dots: methylated CpG.
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molecular biological techniques have provided a chance that they can be directly applied in 
ctDNA collection and validation even smaller amounts of ctDNA [10, 21, 22].
4. Hypermethylation of TSGs in breast cancer: a prognostic and early 
diagnostic indicator
DNA aberrant methylation patterns, like hypermethylation of TSGs, global hypomethylation, 
etc. have been observed in human breast cancer. Silencing of TSGs expression by DNA hyper-
methylation provides a molecular mechanism by which DNA hypermethylation could trigger 
tumour development by interfering with the binding of transcription factors located at TSG 
gene’s promoter. Thus, numerous studies have been attempted to focus on the role of hyper-
methylation of the TSG genes’ promoter in breast cancer as well as the correlation between 
methylation of specific CGIs in TSGs and many breast cancer clinical states. Table 1 shows the 
most relevant hypermethylated genes involve in various functions in breast cancer reported 
so far. Methylation of these TSG promoters is associated with the complete loss of TSG protein 
products in cancer cells and development of malignant phenotype.
This DNA hypermethylation is a reversible signal, maybe due to the activity of Demethylase, 
which performs the reverse reaction to DNA methyltransferase and is an excellent candidate to 
be one of its important partners in shaping the methylation pattern of genomes [23, 24]. Thus, 
nowadays, many studies have been focused on an innovative approach in cancer treatments in 
which aimed to inhibit DNA hypermethylation and/or re-expression of silenced TSGs.
Therein, the hypermethylation of the CGIs promoter of BRCA1 gene is now recognized as 
one of the most common molecular abnormalities associated with breast cancer develop-
ment and is quoted as a significant example. BRCA1 (Breast cancer 1) gene (HGNC: 1100; 
Entrez Gene: 672; OMIM: 113705; UniProtKB: P38398), which locates at 17q12-21, also known 
by many other names such as IRIS, PSCP, BRCAI, BRCC1, RNF53, BROVCA1, etc. is a tumour 
TSGs Function Location
APC Inhibitor of β-catenin, cell proliferation, migration and adhesion 5q21
BRCA1 DNA damage repair 17q21
Cyclin D2 Regulators of CDK kinases 12p13
GSTP1 Conjugation to Glutathione, prevention of oxidative DNA damage 11q13
p16INK4α Cyclin-dependent kinase inhibitor 9p21
PTEN Negatively regulating AKT/PBK signalling pathway 10q23
RARβ Retinoic acid receptor 3p24
RASSF1A Ras effector homologue, cell cycle arrest 3p21
ZMYND10 Inhibitor of colony formation of cancer cells 3p21.3
Table 1. Examples of TSGs that undergo CpG island hypermethylation in breast cancer.
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suppressor gene that conferred genetic pre-disposition to early onset of human breast and 
ovarian cancer [25–27]. This gene encodes a nuclear phosphoprotein that plays a role in 
maintaining genomic stability. The encoded protein combines with many other tumour sup-
pressor, DNA damage sensors, and signal transducers to form a large multi-subunit protein 
complex that is called as BRCA1-associated genome surveillance complex (BASC). Therefore, 
the BRCA1 protein is involved in multifunction, such as repairing damaged DNA of double-
stranded break, transcriptional regulation, ubiquitinylation, recombination and controlling 
the cell cycle check points as well as other functions. The hypermethylation of the BRCA1 
promoter has been considered as an inactivating mechanism of BRCA1 expression, leading 
to breast tumourigenesis. In addition, some evidences have shown the significant association 
between the inactivation or low expression of BRCA1 protein expression and the aberrant 
methylation status of CGIs in the BRCA1 promoter in breast cancer tumorigenesis.
It is well known that breast cancer constitutes a heterogeneous complex of diseases charac-
terized by different distinct morphologies, biological behaviours and clinical outcomes. The 
classification and diagnosis of breast cancer have been based on the expression of different 
proteins, including estrogen receptor (ER), progesterone receptor (PR) and human epidermal 
growth factor receptor 2 (HER2) [28, 29]. An example of such a target molecular therapy is 
Trastuzumab (Herceptin®), which has been approved to directly against HER2-expressing 
tumours. Among the variety of breast cancer types, a subtype called triple-negative breast 
cancer (TNBC), which is clinically defined by the lack of expression of ER, PR and HER2, 
presents a challenge for effective clinical management [28]. Therefore, it is essential to find a 
reliable biomarker, which are not only useful for the screening, early diagnosis and prognosis 
prediction for breast cancer, but also provide insight into the mechanisms driving tumouri-
genesis as well as an innovative approach in breast cancer treatments.
Over the past few years, a considerable amount of studies has been conducted to evaluate the 
association between BRCA1 promoter methylation and many clinicopathological characteristics 
of breast cancer. Therefore, tentatively, a meta-analysis was carried out, a total of 44 studies 
including 25 case-control studies and 19 cohort studies were eligible, enrolled into the meta-
analysis research. According to our research, the prevalence of the hypermethylated BRCA1 pro-
moter has been reported to fall in the range from 9.1 to 59.2%, which was statistically significant 
higher in breast cancers than non-cancerous controls (OR = 4.00, 95% CI= 2.336–6.878, P < 0.001, 
Figure 4). Because of large heterogeneity (P
H
 ≤ <0.0001, I2 = 73.82%), we continued to clarify the 
potential source of heterogeneity via stratified analysis based on sample materials, methods for 
identifying methylation and ethnicity; with the detailed results were summarized in Table 2.
As shown in Table 2, the pooled OR for BRCA1 promoter hypermethylation in breast cancer 
tissues was 4.312 (95% CI = 2.395–7.765, P < 0.001) compared with normal or benign tissues, and 
was higher than the pooled OR in peripheral blood of breast cancer patients (OR = 2.485, 95% CI = 
1.433–4.310, P = 0.001) compared with non-cancer controls. In addition, the pooled OR for BRCA1 
promoter hypermethylation detected by MSP was 5.059 (95% CI = 2.214–11.561, P < 0.001), sig-
nificant higher than other methods (OR = 2.506; 95% CI = 1.409–4.457, P = 0.002). Meanwhile, the 
frequency of BRCA1 promoter hypermethylation in Asians (OR = 4.006, 95% CI = 2.122–7.560; P < 
0.001) was higher than in Caucasians (OR = 2.291, 95% CI = 1.147– 4.576, P = 0.006). Furthermore, 
our studies also demonstrated that the BRCA1 promoter hypermethylation was significant 
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correlated with the clinicopathological characteristics which included ages, meant that the prev-
alence of hypermethylation status was higher in the group of age under 55 (OR = 1.227, 95% CI 
= 1.604–1.414, P = 0.05) (Figure 5); histological grade, meant that the hypermethylated BRCA1 in 
the case of histological grade 3 and 4 was higher than in the histological grade 1 and 2 (OR = 1.858, 
95% CI = 1.499–2.301, P < 0.001) (Figure 6); disease stages, meant that the prevalence of the hyper-
methylation of BRCA1 gene in the case of late stages was higher than in early stages (OR = 1.339, 
95% CI = 1.023–1.752, P = 0.033) (Figure 7). Additionally, the hypermethylation status of BRCA1 
gene’s promoter was correlated with the ER(−) (OR= 2.02, 95% CI = 1.525–2.675, P < 0.001), PR(−) 
(OR = 1.823, 95% CI = 1.374–2.41, P < 0.001) and especially with triple-negative phenotype (OR = 
2.814, 95% CI = 1.811–4.371, P < 0.001) under fixed or random effect mode (Figure 8). Thus, those 
meta-analysis results confirmed that the BRCA1 promoter hypermethylation was significant cor-
related with the increased risk of breast cancer, associated with several specific clinicopatho-
logical characteristics of breast cancer, which indicated that BRCA1 promoter hypermethylation 
could be utilized as an effective biomarker in predictive and diagnostic breast cancer.
Up to now, a significant proportion of breast cancer patients who have poor prognosis will 
develop recurrence. This needs to find a more sensitive and specific biomarker, which can be 
a powerful prognostic indicator and help make therapeutic decisions to prolong the survival 
time of patients. Then, we included 10 articles provide disease-free survival (DFS) and/or 
overall survival (OS) to evaluate the role of the BRCA1 promoter hypermethylation in the 
prognosis of breast cancer. Overall survival (OS), which was defined as the length of time 
from either the date of diagnosis or the start of treatment for breast cancer, that patients 
diagnosed with the disease are still alive, and disease-free survival (DFS), which was defined 
that the length of time after primary treatment for a cancer ends that the patient survives 
Figure 4. Forest plot for evaluating the association between BRCA1 promoter methylation and breast cancer under fixed 
or random effect mode.
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without any signs or symptoms of that cancer. In detail, in the Asian population, the OS and 
DFS were 2.163 (95% CI = 1.212–3.858, P < 0.001) and 2.47 (95% CI = 1.331–4.584, P = 0.004), 
respectively, using single variable analysis. In the case of using multiple variables analysis, 
the OS and DFS were 1.611 (95% CI = 1.116–2.324, P = 0.011), and 2.872 (95% CI = 1.389–
5.937, P = 0.004), respectively. Those analytic results indicated that hypermethylated BRCA1 
gene’s promoter was significant associated with OS, DFS, meant that it was poor prognosis 
to breast cancer patients, in both single and multiple variables analysis. Hence, BRCA1 pro-
moter hypermethylation is suggested to be a potential biomarker for prognostic assessment.
Figure 5. Forest plot for evaluating the association between BRCA1 promoter methylation and ages under fixed or 
random effect mode.
Test of association Test of heterogeneity
Variables N OR (95% CI) Z P-value Model Variables N
Total 25 4.00 (2.336–6.878) 5.04 <0.001 R <0.0001 73.82%
Material
Tissue 22 4.312 (2.395–7.765) 4.87 <0.001 R 0.0003 58.32%
Blood 10 2.485 (1.433–4.310) 3.24 0.001 R 0.0045 60.78%
Methods
MSP 15 5.059 (2.214–11.561) 3.845 <0.001 R 0.0001 67.89%
Others 10 2.506 (1.409–4.457) 3.126 0.002 R 0.0049 61.97%
Ethnicity
Caucasian 10 2.291 (1.147–4.576) 2.349 0.006 R 0.0375 49.25%
Asian 14 4.006 (2.122–7560) 4.282 <0.001 R 0.0060 55.60%
Africa 1 18.5217 (6.917–49.59) 5.809 <0,001 NA NA NA
Note: N: the total number of eligible studies; Caucasians included: American and Europeans, Australians. PH: the P-value 
of Q test for heterogeneity among studies; F: fixed-effects model; R: random-effects model; NA: non-analysis.
Table 2. Overall and subgroups analyses of BRCA1 methylation and breast cancer risk in 25 cases control studies.
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Figure 6. Forest plot for evaluating the association between BRCA1 promoter methylation and histological tumour 
grades under fixed or random effect mode.
Figure 7. Forest plot for evaluating the association between BRCA1 promoter methylation and disease stages under fixed 
or random effect mode.
Figure 8. Forest plot for evaluating the association between BRCA1 promoter methylation and triple negative phenotype 
under fixed or random effect mode.
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5. DNA hypermethylation-targeted drug in cancer therapy
The process of DNA methylation is catalysed by DNMTs which typically occurs at CpG 
dinucleotides. As mentioned earlier, it is also a reversible process. Removal of a methyl group 
from DNA must involve a cleavage of a carbon-carbon bond, which is carried out by DNA 
demethylase (dMTase). In addition, the methylation reaction can be blocked by the inhibi-
tors of DNA methylation drugs, such as 5-azacytidine, 5-aza-2′-deoxycytidine, etc. which 
contains a nitrogen in the place of carbon at 5′ position of cytosine ring (Figure 9) [30]. This 
drug is cooperated into DNA, then, replaces the natural base cytosine and acts as a potent 
inhibitor of the DNMTs, inducing the DNA demethylation [31]. Since DNA methylation is 
reversible, an aberrant hypermethylation of tumour suppression genes can be reverted. This 
consequently supports DNA methyltransferases (DNMTs) as attractive therapeutic targets. 
Indeed, epigenetic drugs (epi-drug)—methylation inhibitors through DNMT inactivation, 
used alone or in combination with other biomarkers, including by dietary agents, for tar-
geted preventive and therapeutic interventions, have attracted attention recently.
DNMT inhibitors (DNMTi), such as 5-azacytidine (azacitidine) and 5-aza-2′-deoxycytidine 
(decitabine) (Figure 10), are epi-drugs which are first announced and currently marketed as 
hypomethylation therapeutics. They are nucleoside analogues, derivatives of cytidine that 
work by incorporating into the DNA sequence at cytosine positions during DNA replication 
to be active and then form a suicidal covalent complex with the DNMTs. These drugs have 
been approved by Food and Drug Administration (FDA) for clinical tests on the myelodys-
plastic syndrome, malignant mesothelioma, pre-leukemic disease, breast cancer, nasopharyn-
geal carcinoma and some other diseases.
Figure 9. Inhibition of DNMTs by 5-azacytidine.
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Zebularine is another cytidine analog that has a mechanism similar to 5-azacytidine, integrat-
ing into DNA and forming a covalent bond with DNMT1, resulting in inhibition of methyla-
tion reaction. Moreover, Zebularine is reported that it is a DNMT1 inhibitor with low toxicity 
and has a high sensitivity in selective cancer cells. Particularly, this drug showed the reacti-
vated functions on some important tumour suppressor genes that were disrupted in breast 
cancer cell lines, even at low concentrations. Although the drug is not yet FDA approved, a 
preclinical study on mouse models showed that Zebularine can inhibit DNA methylation and 
induce re-expression-silenced gene, even given orally.
Other trends related to DNA methylation including the inhibition of DNMTs through siRNA, 
ribozymes, antisense oligonucleotides have also been considered. Some drugs have proven 
effective impact on cell cultures, animal models and clinical trials as well such asMG98, a 20 
bp anti-sense oligonucleotide that directly prevents the translation of DNMT1 or RG108—a 
new small molecule that can act on active site of DNMT1. Unlike the nucleoside analogs, 
RG108 did not demonstrate cytotoxic or genotoxic effects on cells even at high concentrations.
The combination of the histone deacetylase inhibitors (HDACi), such as Trichostatin A (TSA) 
and phenylbutyrate, with DNMTi is a new trend giving promising efficacy in the treatment of 
cancer. In breast cancer, triple negative metastatic patients that do not express estrogen recep-
tor (ER), progesterone receptor (PR) and HER, do not respond to agents such as trastuzumab 
(Herceptin) and tamoxifen. Particularly, the loss of ER in some triple negative breast cancers 
is epigenetically silenced by abnormal methylation and histone modifications. Consequently, 
the patients express the resistance of anti-estrogen. Triple negative metastatic breast cancer 
patients were pre-treated with decitabine—a DNMTi and LBH 589—an HDACi, to restore 
the ER and then treated with tamoxifen. This combination can remove the epigenetic modi-
fications including DNA methylation and histone deacetylation and reactivate ER. Thus, this 
reactivated ER cells become sensitive to agents like tamoxifen. Similarly, the combination of 
azacitidine with TSA also induces the re-expression of ER function to increase the sensitiv-
ity of breast cancer cell lines that previously show negative expression with ER in tamoxifen 
therapy or the combination of HDACi and trastuzumab has taken to effectively suppression 
of the development and apoptosis induction into breast cancer cells lines.
In addition, the combination of epi-drugs with chemotherapeutic agents or natural dietary 
ingredients also increases the effectiveness of treatment. A pre-clinical study has shown 
that the combination of decitabine and docetaxel (an anti-mitotic drug) can increase treat-
Figure 10. The structure of 5-azacytidine and 5-aza-2′-deoxycytidine.
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ment outcomes against cancer cells in experiments conducted on breast cancer cell lines [32, 
33]. Decitabine in combination with another substance, amsacrine or idarubicin, also shows 
therapeutic effect. Green tea polyphenol, (-)-epigallocatechin-3-gallate (EGCG), may cause 
re-modelling of chromatin structure and the ERα promoter by histone acetylation and DNA 
methylation mechanisms, and consequently reactivating ERα. The combination of TSA and 
EGCG leads to reactivation of numerous tumour suppressor genes by inhibiting directly or 
indirectly DNMTs. Dietary sulforaphane—an inhibitor of histone acetylation also shows very 
effective activity in the inhibition of proliferation and survival of breast cancer cells without 
affecting normal cells.
Therefore, methylation combined therapy is very promising in the treatment of breast can-
cer. Clinical trials in the combination of trastuzumab with HDACi for the treatment of breast 
cancer, and a phase II trial in breast cancer—valproic acid combined with FEC100 (5-fluo-
rouracil, epirubicin and cyclophosphamide) also are being investigated. Up to date, sev-
eral other classes of epi-drug have been studied, developed with new drugs, which based 
on the DNMT inhibitors, HDAC inhibitors, HMT inhibitors, etc. in early preclinical trial 
development.
6. Conclusion
DNA hypermethylation has become established in recent years as being one of the important 
causes of breast tumorigenesis and potential biomarkers in clinical applications, prognosis 
and early diagnosis of breast cancer. As the release of tumour-associated DNA into body flu-
ids, thus the screening of plasma or serum DNA may provide information on epigenetic pro-
files which are tightly associated with breast cancer development, progression and response 
to therapies. This is the real advantage of an aberrant DNA methylation property as a great 
versatility, promising biomarker for the molecular monitoring of cancer patients, and applied 
in early detection, prognosis and predicting drug sensitivity in cancer.
Abbreviations
APC Adenomatous Polyposis Coli
BASC BRCA1-associated genome surveillance complex
BRCA1 Breast cancer 1
CGIs CpG islands
CI Confidence interval
ctDNA Cell-free circulating tumour DNA
DFS Disease free survival
DNMTi DNA methyltransferase inhibitors
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DNMTs DNA methyltransferase
ER Receptor
FDA The Food and Drug Administration
GSTP1 Glutathione S-transferase P1
HDACi Histone deacetylase inhibitors
HER2 Human epidermal growth factor receptor 2
m5CpG Methyl-5-CpG
MBD Methyl-CpG binding domain protein
OR Risk ratio
OS Overall survival
p16INK4α CDK4 Inhibitor p16-INK4α
PR Progesterone receptor
PTEN Phosphatase and Tensin homolog
RARβ Retinoic Acid Receptor Beta
RASSF1A Ras Association domain Family 1 isoform A
TNBCs Triple-negative breast cancer
TSA Trichostatin A
TSG Tumour suppressor gene
ZMYND10 Zinc Finger MYND-Type Containing 10
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